Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

PHASE2TerminatedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

December 13, 2021

Study Completion Date

January 28, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Liquid Alpha1-Proteinase Inhibitor (Human)

Intravenous infusion 120 mg/kg

DRUG

Placebo

Intravenous infusion

DRUG

Standard Medical Treatment

SMT

Trial Locations (20)

10032

Columbia University Medical Center, New York

33125

University of Miami Hospital, Miami

35233

Birmingham VA, Birmingham

38104

Memphis VA, Memphis

48912

Sparrow Hospital, Lansing

63401

Hannibal Clinic, Hannibal

64128

Kansas City VA, Kansas City

66465

Unidad Medica para la Salud Integral, San Nicolás de los Garza

68102

CHI Health Center, Omaha

84108

University of Utah, Salt Lake City

85013

St. Joseph's Hospital, Phoenix

2340000

Hospital Carlos Van Buren, Valparaíso

8860000

Hospital Padre Hurtado, Santiago

89020-430

AngioCor Blumenau, Blumenau

88811-500

Sociedade Literaria e Caritativa Santo Agostinho, Criciúma

18618-686

Universidade Estadual São Paulo - Campus de Botucatu, Botucatu

89030-101

Hospital Dia do Pulmão, Blumenau

01327-001

Hospital Alemao Oswaldo Cruz, São Paulo

04037-002

Universidade Federal de Sao Paulo, São Paulo

Unknown

Fundación Oftalmológica de Santander, Bucaramanga

Sponsors
All Listed Sponsors
lead

Grifols Therapeutics LLC

INDUSTRY